

## Joint Symposium 9

EANM / European Society for Molecular Imaging (ESMI) / European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Friday, October 23, 13:50-15:20

### Session Title

**Imaging Pulmonary Fungal Infections**

### Chairperson

Giorgio Treglia (Bellinzona, Switzerland)

### Programme

- 13:50 - 14:14 Maurizio Sanguinetti (Rome, Italy / ESCMID): Current Dilemmas in Fungal Treatment
- 14:14 - 14:34 Greetje Vande Velde (Leuven, Belgium / ESMI): Preclinical Tools to Study Fungal Infections
- 14:34 - 14:54 Leo Carlin (Glasgow, United Kingdom): In vivo Imaging of Host Responses
- 14:54 - 15:18 Mathias Gunzer (Essen, Germany): Imaging Pulmonary Infections in the Clinic

### Educational Objectives

1. Understand the clinical needs in diagnosis and follow-up of pulmonary fungal infections
2. Better understand the potential roles and contributions of preclinical imaging tools in fungal infection research
3. Get an overview of current developments that may impact clinical patient management in the near future

### Summary

Pulmonary fungal infection is a common complication in immune compromised patients and associated with impaired clinical outcome [Hayes et al. *Curr Opin Pulm Med* 2013]. For example, small studies suggest that  $^{18}\text{F}$ -FDG-PET/CT is more sensitive than CT alone to detect *Aspergillus* lesions. In 10 patients with definitive or probable invasive *Aspergillus* with FDG-positive lesions, CT showed corresponding lesions in 7/10 patients [Hot et al. *Clin Microbiol Infect* 2011]. Importantly, the immune compromised condition of the host does not compromise the ability of  $^{18}\text{F}$ -FDG-PET/CT to detect pulmonary *Aspergillus* lesions. In a prospective observational study, the presence of  $^{18}\text{F}$ -FDG-positive pulmonary lesions was highly associated with possible or probable invasive *Aspergillus* infection in severe neutropenic patients; 5/7 patients. To the contrary, only in 2/21 patients without invasive fungal disease,  $^{18}\text{F}$ -FDG-positive pulmonary lesions were observed [Vos et al. *Eur J Nucl Med Mol Imaging* 2012].  $^{18}\text{F}$ -FDG-PET/CT might well be able to differentiate between invasive and non-invasive *Aspergillus* based on  $^{18}\text{F}$ -FDG-uptake patterns. A retrospective study in 24 patients, Invasive Pulmonary Aspergillosis (IPA) was associated with multiple lesions, hypermetabolic nodules (as compared to the mediastinal blood pool) and high  $\text{SUV}_{\text{max}}$  (median 4.5, range 1.3-8.9). Non-IPA on the other hand is more often a single lesion with a isometabolic halo pattern and lower  $\text{SUV}_{\text{max}}$  (median 1.6, range 0.5-3.1) [Kim et al. *J Comput Assist Tomogr* 2013].  $^{18}\text{F}$ -FDG-PET/CT can potentially be used to monitor disease activity after initiation of anti-fungal therapy. Decreased or absent FDG-uptake in a previously  $^{18}\text{F}$ -FDG-positive pulmonary *Aspergillus* lesion is frequently observed upon treatment [Ozsahin et al. *Blood* 1998].

### Key Words

PET, *Aspergillus*, fungal, infection, lung